Premarket Alert: AMAG Pharmaceuticals (AMAG)

Posted in General 
July 1st, 2009

AMAG Pharmaceuticals Inc. (Nasdaq: AMAG) are up about 6 percent with more than 17,000 shares traded as of 8 a.m. Eastern this morning, after the FDA approved the company’s Feraheme drug as an iron replacement therapy for patients with chronic kidney disease.

The approval removes an overhang for the company. It first sought FDA approval for the drug in December 2007, and twice received requests for more information on it last year.

The company expects to make Feraheme available in late July. — Mike Tarsala

Comments are closed

-->